# Fabomotizole

**Cat. No.:** HY-14895

**CAS No.:** 173352-21-1

**Molecular Formula:** $C_{15}H_{21}N_3O_2S$

**Molecular Weight:** 307.41

**Target:** Others

**Pathway:** Others

**Storage:**

| | | |
|---|---|---|
| Pure form | -20°C | 3 years |
| In solvent | -80°C | 6 months |
| | -20°C | 1 month |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 100 mg/mL (325.30 mM; Need ultrasonic)

| Preparing Stock Solutions | Mass / Solvent / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 3.2530 mL | 16.2649 mL | 32.5298 mL |
| | 5 mM | 0.6506 mL | 3.2530 mL | 6.5060 mL |
| | 10 mM | 0.3253 mL | 1.6265 mL | 3.2530 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (8.13 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (8.13 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (8.13 mM); Clear solution

## BIOLOGICAL ACTIVITY

**Description**

Fabomotizole (CM346) is an anxiolytic agent. Fabomotizole produces anxiolytic and neuroprotective effects without any muscle relaxant actions.

**In Vitro**

Afobazole's mechanism of action remains poorly defined however, with GABAergic, NGF and BDNF release promoting, MT1 receptor antagonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Afobazole was shown to inhibit MAO-A reversibly and there might be also some involvement with serotonin receptors. Afobazole has found little clinical use outside of Russia and has not been evaluated by the FDA.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Afobazole, From Wikipedia



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA